Compelling Interim Results from QART Medical’s Multi-center Clinical Outcome Study Presented at ESHRE 2024 Annual Meeting

COMPELLING INTERIM RESULTS FROM QART MEDICAL’s MULTI-CENTER CLINICAL OUTCOME STUDY PRESENTED AT ESHRE 2024 ANNUAL MEETING

Raanana, Israel;

QART Medical is excited to announce that the company’s work was presented at the European Society Of Human Reproduction and Embryology (ESHRE) Annual Meeting 2024. This year’s ESHRE conference took place in Amsterdam from July 7-10. Dr. Bujana Sa`ar-Ris, MD, head of BMC’s (Barzilai medical center, Ashkelon, Israel) IVF unit and Dr. Yulia Michailov, PhD, manager of BMC’s IVF lab, presented QART Medical outcome study results.

The paper presented, titled “Preliminary Clinical Outcome Using the Q300™ Device in a Reproductive Laboratory Environment”, summarizes the first 24 cases that the BMC team conducted in their IVF unit, which was the pioneering site for this study.

This study is meant to assess the impact of using QART’s Q300™ system under routine IVF workflow. The data presented was based on a cutoff after 24 initial couples enrolled into the study, and shows an increase of 75% in chances of having a usable embryo for transfer on day 3, an increase of 35% in the chances of having a good blastocysts for transfer on day 5 and an increase of 100% in the chances of generating clinical pregnancy, following chemical pregnancy (i.e., positive beta hormone test).

Additional IVF units have since joined this multi-center study, and results from a larger and more diversified cohort of patients are due to be released in Q4 2024. The image below shows Dr Sa’ar-Ris (left) and Dr Michailov at ESHRE 2024 adjacent the e-poster presentation of the study results.

“This is an exciting point in time for male fertility and IVF specialists. QART’s product – Q300™ – is the first to allow IVF clinicians harness the power of highly-informative holographic imaging and advanced machine vision, to examine compliance of individual sperm cells with consensus WHO criteria for good human sperm morphology. This is achieved as part of the routine IVF workflow. We extend our deep gratitude to the Barzilai IVF team for their continued scientific and clinical pioneering collaboration” says Alon Shalev, CEO of QART Medical.